



Substitute for FORM 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number:	11/781,254
Filing Date:	February 18, 2004
First Named Inventor:	Joel Bernstein
Group Art Unit:	1617
Confirmation Number:	3157
Examiner Name:	Kim, Jennifer M.
Attorney Docket Number:	41959-102742

U.S. PATENT DOCUMENTS

U.S. Patent Document				Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code			
	4	4,636,125		Burgard	Jan. 13, 1987	

FOREIGN PATENT DOCUMENTS

Foreign Patent Document					Name of Patentee or Applicant	Date of Publication	Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.				Translation	
						Yes	No**
	5	Otsuki et al., "Comparison of Pharmacological Activities of Doxepin Hydrochloride with Its Geometrical Isomers," <i>Oyo Yakuri</i> , 6 (5): 973-984 (1972) (Abstract).					
	6	Pinder et al., "Doxepin Up-to-date: A Review of its Pharmacological Properties and Therapeutic Efficacy with Particular Reference to Depression," <i>Drugs</i> , 13: 161-218 (1977).					
	7	Ross, CRC Handbook of Stereoisomers: Drugs in Pharmacology, "Antidepressant Drugs: (Z)- and (E)-Isomers," CRC Press, Boca Raton, Fla., pp. 243-255 (1984)					
	8	Yan et al., "Absolute bioavailability of a stereoselective pharmacokinetics of doxepin," <i>Xenobiotica</i> , 32 (7): 615-623 (2001).					
	9	Copy of International Search Report issued in PCT/US2003/36600 (2004).					
	10	Copy of Page 1 of Office Action issued in GB2411356 (2005).					

CHDS01 AOM 497905v1

EXAMINER	DATE CONSIDERED
----------	-----------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

* An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).